EE200200693A - Interferoon hulgiskleroosi raviks - Google Patents

Interferoon hulgiskleroosi raviks

Info

Publication number
EE200200693A
EE200200693A EEP200200693A EEP200200693A EE200200693A EE 200200693 A EE200200693 A EE 200200693A EE P200200693 A EEP200200693 A EE P200200693A EE P200200693 A EEP200200693 A EE P200200693A EE 200200693 A EE200200693 A EE 200200693A
Authority
EE
Estonia
Prior art keywords
interferon
treatment
multiple sclerosis
sclerosis
Prior art date
Application number
EEP200200693A
Other languages
English (en)
Estonian (et)
Inventor
M. Croze Edward
Faulds Daryl
Charis Wagner T.
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of EE200200693A publication Critical patent/EE200200693A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EEP200200693A 2000-06-16 2001-06-18 Interferoon hulgiskleroosi raviks EE200200693A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21204600P 2000-06-16 2000-06-16
US09/881,050 US20020025304A1 (en) 2000-06-16 2001-06-15 Novel interferon for the treatment of multiple sclerosis
PCT/US2001/041022 WO2001095929A2 (en) 2000-06-16 2001-06-18 Interferon for treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
EE200200693A true EE200200693A (et) 2004-06-15

Family

ID=26906704

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200693A EE200200693A (et) 2000-06-16 2001-06-18 Interferoon hulgiskleroosi raviks

Country Status (22)

Country Link
US (1) US20020025304A1 (xx)
EP (1) EP1289541A2 (xx)
JP (1) JP2004505021A (xx)
KR (1) KR20030009529A (xx)
CN (1) CN1436086A (xx)
AU (1) AU2001267099A1 (xx)
BG (1) BG107370A (xx)
BR (1) BR0111852A (xx)
CA (1) CA2413077A1 (xx)
CZ (1) CZ20024094A3 (xx)
EE (1) EE200200693A (xx)
HU (1) HUP0300787A2 (xx)
IL (1) IL152996A0 (xx)
LT (1) LT2002123A (xx)
MX (1) MXPA02012308A (xx)
NO (1) NO20025964L (xx)
NZ (1) NZ522849A (xx)
PL (1) PL359562A1 (xx)
RU (1) RU2003100517A (xx)
SI (1) SI21080A (xx)
SK (1) SK17612002A3 (xx)
WO (1) WO2001095929A2 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1565205A4 (en) * 2002-11-18 2006-07-05 Maxygen Inc INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
EP1712992A1 (en) * 2005-04-11 2006-10-18 Sony Ericsson Mobile Communications AB Updating of data instructions
US8895700B2 (en) 2010-02-18 2014-11-25 Janssen Biotech, Inc. Monkey homolog of human interferon omega
CN109071627B (zh) 2016-02-05 2023-04-04 奥里尼斯生物科学私人有限公司 Cd8结合剂
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
IL268346B2 (en) 2017-02-06 2024-08-01 Orionis Biosciences BV Targeted chimeric proteins and their uses
US20240309062A1 (en) * 2023-03-16 2024-09-19 A-Alpha Bio Interferon alpha-2 variants

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
HUT76099A (en) * 1994-05-10 1997-06-30 Immulogic Pharma Corp Compositions and treatment for multiple sclerosis
AU761577C (en) * 1997-12-08 2004-02-05 Genentech Inc. Human interferon-epsilon: a type I interferon
EP1082132A1 (en) * 1998-05-29 2001-03-14 Biogen, Inc. Recombinant human interferon beta-1a (ifn-beta-1a) formulation
EP1141296A2 (en) * 1998-09-18 2001-10-10 ZymoGenetics, Inc. Interferon-epsilon
AU2001255380A1 (en) * 2000-04-14 2001-10-30 Zymogenetics Inc. Human interferon, zinf2

Also Published As

Publication number Publication date
JP2004505021A (ja) 2004-02-19
SI21080A (sl) 2003-06-30
US20020025304A1 (en) 2002-02-28
RU2003100517A (ru) 2004-06-27
NO20025964L (no) 2003-02-14
BR0111852A (pt) 2003-05-20
SK17612002A3 (sk) 2003-08-05
PL359562A1 (en) 2004-08-23
CZ20024094A3 (cs) 2003-05-14
WO2001095929A3 (en) 2002-10-10
BG107370A (en) 2003-11-28
AU2001267099A1 (en) 2001-12-24
LT2002123A (en) 2003-06-25
CA2413077A1 (en) 2001-12-20
NO20025964D0 (no) 2002-12-12
KR20030009529A (ko) 2003-01-29
IL152996A0 (en) 2003-06-24
NZ522849A (en) 2004-05-28
HUP0300787A2 (hu) 2003-07-28
WO2001095929A2 (en) 2001-12-20
MXPA02012308A (es) 2003-04-25
EP1289541A2 (en) 2003-03-12
CN1436086A (zh) 2003-08-13

Similar Documents

Publication Publication Date Title
DE60142412D1 (de) Stabilisiertes interleukin 2
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
NO20042154L (no) Terapeutiske isokinolinforbindelser
EE05020B1 (et) Glburiidi ravimkoostis
NO20033205D0 (no) Terapeutiske kromanforbindelser
NO20032122L (no) Forbedret behandling
DE50209245D1 (de) Neuroprotektives medikament
NO20032033L (no) Stabiliserte interferonsammensetninger
DK1326628T3 (da) Kemokinmutanter til behandling af dissemineret sklerose
DE60227963D1 (de) Behandlungssystem
EE200200693A (et) Interferoon hulgiskleroosi raviks
FR2791258B1 (fr) Composition amincissante
GB0114231D0 (en) Treatment of multiple sclerosis
ID30381A (id) Penggunaan arilalkanoilpiridazina
PL350883A1 (en) One-track roller-board
ITMI20011820A0 (it) Trattamento di ustioni
DE60207900D1 (de) "Suspend"-Paketübertrager
FR2828374B1 (fr) Bordure d'allee
NO20022643D0 (no) Reduksjonsprosess
IL136687A0 (en) Pharmaceutical composition for the treatment of multiple sclerosis
SE0102496L (sv) Utslagsramp
SE0100081L (sv) Utslagsramp
SE0002001D0 (sv) Surface treatment composition
ITRC20010003A1 (it) "fumanello"
SE0103855D0 (sv) Therapeutic agents